製品名:3-(2,5-dichloropyrimidin-4-yl)-6-methyl-1H-indole

IUPAC Name:3-(2,5-dichloropyrimidin-4-yl)-6-methyl-1H-indole

CAS番号:2241134-68-7
分子式:C13H9Cl2N3
純度:95%+
カタログ番号:CM1075711
分子量:278.14

包装単位 有効在庫 価格(USD) 数量

研究開発用専用.

問い合わせフォーム

   refresh    

製品詳細

CAS番号:2241134-68-7
分子式:C13H9Cl2N3
融点:-
SMILESコード:CC1=CC2=C(C=C1)C(=CN2)C1=C(Cl)C=NC(Cl)=N1
密度:
カタログ番号:CM1075711
分子量:278.14
沸点:
MDL番号:
保管方法:

Category Infos

Indoles
Indole is a compound of pyrrole and benzene in parallel, also known as benzopyrrole. There are two combinations of pyrrole and benzene, called indole and isoindole, respectively. Many derivatives of indole have physiological and pharmacological activities, and can synthesize vasodilators, antihistamines, antipyretic analgesics, etc. in medicine, so indole is also a very important heterocyclic compound.
indole company
As a indole company,we sincerely welcome the new and old friends from home and abroad to synergize with our company and share the benefits and opportunities.

Column Infos

Tuspetinib
Venetoclax (VEN) combined with a hypomethylating agent (HMA) has proven effective for treating acute myeloid leukemia (AML) patients who are ineligible for intensive chemotherapy. However, this combination therapy still faces issues such as low response rates, limited survival, and potential resistance to VEN.
Aptose’s Tuspetinib (TUS) is a multi-kinase inhibitor selectively targeting SYK, RSK, FLT3 , JAK1/2, KIT, which drive proliferation in AML. The addition of Tuspetinib into VEN and HMA therapy improves medical efficacy and and may help prevent resistance to both agents. TUS+VEN+HMA triplet protocol in frontline therapy for newly diagnosed (ND) AML is currently being tested in a global phase 1/2 trial.

Related Products